• Publications
  • Influence
A Multi-center, Dose-escalation Study of Human type I Pancreatic Elastase (PRT-201) Administered after Arteriovenous Fistula Creation
Purpose To explore the safety and efficacy of PRT-201. Methods Randomized, double-blind, placebo-controlled, single-dose escalation study of PRT-201 (0.0033 to 9 mg) applied after arteriovenousExpand
  • 43
  • 1
  • PDF
Application of Human Type I Pancreatic Elastase (PRT-201) to the venous Anastomosis of Arteriovenous Grafts in Patients with Chronic Kidney Disease
Purpose To explore the safety and efficacy of PRT-201 applied to the outflow vein of a newly created arteriovenous graft (AVG). Methods Randomized, double-blind, placebo-controlled, single-doseExpand
  • 29
  • 1
  • PDF
The ability of serum from alpha 1‐antitrypsin–deficient patients to inhibit PRT‐201, a recombinant human type I pancreatic elastase
PRT‐201 is a recombinant human pancreatic elastase under development as a treatment for blood vessels to promote hemodialysis access patency. Proteases such as elastase are normally inactivated byExpand
  • 10
Recombinant Human Elastase Alters the Compliance of Atherosclerotic Tibial Arteries After Ex Vivo Angioplasty
Purpose: This study was designed to determine whether vonapanitase (formerly PRT-201), a recombinant human elastase, treatment can fragment the protein elastin in elastic fibers and cause dilation ofExpand
  • 6
Effects of Recombinant Human Type I Pancreatic Elastase on Human Atherosclerotic Arteries
Rationale: At physiologic pressures, elastic fibers constrain artery diameter. Local treatment of atherosclerotic arteries with PRT-201, a recombinant type I elastase, could result in fragmentationExpand
  • 3
  • PDF
Studies of human pancreatic elastase treatment of rabbit and human vein rings to predict human therapeutic doses
Vascular tissue contains abundant elastic fibers that contribute to vessel elasticity. Vonapanitase (formerly PRT‐201) is a recombinant human chymotrypsin‐like elastase family member 1 (CELA1) shownExpand
  • 2
Recombinant Human Elastase Treatment of Cephalic Veins.
BACKGROUND Vessel injury at the time of Arteriovenous Fistula (AVF) creation may lead to neointimal hyperplasia that impairs AVF maturation. Vonapanitase, a recombinant human chymotrypsin-likeExpand
  • 2
  • PDF
In Vitro Study of a Medical Device to Enhance Arteriovenous Fistula Eligibility and Maturation
The arteriovenous fistula eligibility (AFE) system (Flow Forward Medical, Olathe, KS) is a small, temporary, wearable rotary blood pump system designed to rapidly dilate peripheral veins inExpand
  • 4
Data-Based Modelling of the Arteriovenous Fistula Eligibility (AFE) System for Wall Shear Stress Estimation
The AFE System is a medical device intended to dilate the cephalic vein by increasing the blood flow and wall shear stress (WSS) in the vein over a period of 10-14 days prior to creation of an arteriovenous fistula . Expand
  • 1